What is the clinical evidence from this study?

Study design: Other. Population: Pulmonary arterial hypertension. Intervention: CNP-53 vs. Vehicle. Primary outcome: Right ventricular systolic pressure (RVSP) and right ventricle weight/left ventricle plus interventricular septum weight [RV/(LV + IVS)] ratio.

What question did this study set out to answer?

This research aims to understand how C-type natriuretic peptide (CNP) and guanylyl cyclase-B (GC-B) signaling impact the development of pulmonary arterial hypertension (PAH).

March 19, 2026Open Access

Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension

Key Result

Continuous administration of CNP-53 prevented the development of pulmonary hypertension in mouse models via endothelial GC-B signaling and ameliorated severe PAH in rodent models.

Key Points

This research aims to understand how C-type natriuretic peptide (CNP) and guanylyl cyclase-B (GC-B) signaling impact the development of pulmonary arterial hypertension (PAH).
Used genetically modified mice to analyze the role of endothelial CNP and GC-B in pulmonary hypertension development.
Measured expression levels of related genes like Edn1 and Il6 in various mouse models.
Administered CNP and assessed its effects on pulmonary arterial hypertension progression.
Mice with impaired endothelial CNP/GC-B signaling exhibited more severe pulmonary hypertension.
CNP administration effectively prevented pulmonary hypertension in certain mouse models.
CNP showed additional therapeutic benefits when paired with established treatments.

Structured PICO

Does C-type natriuretic peptide (CNP) administration prevent or improve pulmonary arterial hypertension in preclinical models?

Population

Preclinical models including endothelial cell-specific CNP or GC-B conditional knockout (CNP ecKO or GC-B ecKO) mice, smooth muscle cell-specific GC-B conditional knockout (GC-B smcKO) mice, Sugen5416-hypoxia PAH models (mice and rats), and cultured human pulmonary arterial endothelial cells (HPAECs).

Intervention

C-type natriuretic peptide (CNP) administration

Comparator

Genetic controls (e.g., Tie2-Cre mice) and vehicle/no administration

Outcome

Development and severity of pulmonary hypertension (PH)surrogate

Endothelial CNP/GC-B signaling exerts pivotal preventative and therapeutic effects against the development of pulmonary hypertension in preclinical models, highlighting CNP as a potential therapeutic target for PAH.

Abstract

Abstract C-type natriuretic peptide (CNP) is released from endothelial cells and acts as an autocrine/paracrine mediator, regulating systemic blood pressure and vascular remodeling via guanylyl cyclase-B (GC-B) and natriuretic peptide receptor-C. We investigate the impact of vascular CNP/GC-B signaling on the development of pulmonary arterial hypertension (PAH). Mice developing pulmonary hypertension (PH) show reduced pulmonary NPPC and NPR2 expression than mice without PH. S imilarly, endothelial cells (EC) from patients with idiopathic PAH exhibit lower NPPC and NPR2 expression than control EC. EC-specific CNP or GC-B conditional knockout (CNP ecKO or GC-B ecKO) mice, but not smooth muscle cell-specific GC-B conditional knockout (GC-B smcKO) mice, show more severe PH and greater expression of Edn1, Il6, Ccl2 and Tgfb1 mRNAs than their genetic controls in PAH models. CNP suppresses hypoxia-induced increases in expression of these mRNAs and restored SMAD2/3-SMAD1/5/9 balance in cultured human pulmonary arterial EC. Moreover, CNP administration prevents PH in genetic control and GC-B-smcKO mice but not in GC-B ecKO mice. CNP administration also has therapeutic effects against Sugen5416-hypoxia PAH models as well as additive benefits with established therapies. Endothelial CNP/GC-B signaling thus exerts pivotal preventative effects against development of PH, suggesting the therapeutic potential of CNP for PAH.

Mark Helpful

Bookmark

Relay

View Full Paper